• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 25
      Evolution, and current and future role of radiotherapy in the treatment of haematological malignancies - 1 year(s) ago

      Haematological malignancies are generally highly radiosensitive. Radiotherapy for these diseases was introduced shortly after the discovery of x-rays, and early development happened in a setting where such therapy was the only effective, and possibly curative, treatment method. Advances in technology in the 1950s and 1960s led to very extensive treatment fields, planned with the crude two-dimensional techniques available, to doses of 36–40 Gy or even higher. With the sparse knowledge of the underlying biology of these diseases, roughly the same principles were used in all patients.

      Source: www.thelancet.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        "Modern radiotherapy... is a highly varied and individualised treatment, based on advanced imaging, sophisticated treatment techniques, and an understanding of the biological diversity" @LenaSpecht1 on #radiotherapy in #hemonc in this special issue🧵⬇️ https://t.co/ajHHA1q1dB

    • Mashup Score: 21
      Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA - 1 year(s) ago

      Combination treatment of low-dose, single-fraction radiotherapy with pembrolizumab was safe, with early promise of response activity. Our approach could be an option for patients with relapsed or refractory multiple myeloma who have not responded to previous treatment. Larger trials to substantiate our findings are needed.

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        NEW: a pilot, phase 2 trial showed pembrolizumab and low-dose, single-fraction radiotherapy was safe, with early promise of response activity in patients with relapsed or refractory multiple myeloma #radonc #mmsm https://t.co/yhTlzn6e9z https://t.co/r8D5ucgD4k

    • Mashup Score: 32
      The development of academic CAR T cells - 1 year(s) ago

      Chimeric antigen receptor (CAR) T cells have transformed the way that multiple haematological malignancies are managed. In the EU, six products manufactured by four marketing authorisation holders (MAHs) are currently approved for 14 indications (appendix pp 1–2). The availability of these products has undoubtedly improved the prospects of many patients with these diseases, but it has also created substantial inequalities due to lack of access within the EU and across the globe.

      Source: www.thelancet.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        "We are convinced that #academic CAR T-cell therapy will play an increasingly important role in cancer therapeutics... It would be unfair to leave our patients to their own devices when there is so much we can do for them" In Focus #CARtx @hospitalclinic https://t.co/oJpIzAjdhj

    • Mashup Score: 1
      UK tainted blood: amplifying the voices of the victims - 1 year(s) ago

      On May 20, 2024, the final report on the UK Infected Blood Inquiry was finally published. The inquiry was set up in 2017, after years of campaigning by the victims and families who received contaminated blood in the 1970s and 1980s, leaving up to 30 000 people infected with hepatitis and HIV. According to the report, more than 3000 preventable deaths so far are attributable to infected blood and blood products, which make this scandal the largest disaster in the history of the National Health Service (NHS).

      Source: www.thelancet.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        “We hope that by raising awareness of the mistakes and negligence committed, we can support those awaiting justice… and contribute to the prevention of any more avoidable deaths related to, what should be, live-saving blood products” Editorial https://t.co/xLRNINgaJn

    • Mashup Score: 54
      The Lancet Haematology, August 2023, Volume 10, Issue 8, Pages e557-e694 - 1 year(s) ago

      Explore the current issue of The Lancet Haematology, a monthly journal dedicated to publishing content that advocates change in, or illuminates, haematological clinical practice

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        Our August issue is out! Packed with #sicklecell disease content: our Commission, a #GBD study on #sicklecell, and several associated pieces Also trials on AML, #HIV-related HL, and #menstrualbleeding in VWD #leusm #lymsm #bleedingdisorders ➡️https://t.co/EyrqUdHpyd https://t.co/Uva1tqkJHW

    • Mashup Score: 3
      Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study - 1 year(s) ago

      Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile.

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        Online now: https://t.co/LTeaZNWgpb

    • Mashup Score: 8
      Improving outcomes in sickle cell disease - 1 year(s) ago

      Commissioners Dr Michael R DeBaun and Dr Dipty Jain, and Lwimba Kasongo, MPH, who has lived experience of sickle cell disease, outline some of the obstacles …

      Source: www.youtube.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        @JanetDaby 📽️ To support this @UKParliament launch, we have recorded a new video on #sicklecell disease with @lwimbaa, Prof Michael DeBaun, and Prof Dipty Jain Watch it @TheLancet YouTube channel https://t.co/s8skVGYXgf

    • Mashup Score: 2
      Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021 - 1 year(s) ago

      Our findings show a strikingly high contribution of sickle cell disease to all-cause mortality that is not apparent when each death is assigned to only a single cause. Sickle cell disease mortality burden is highest in children, especially in countries with the greatest under-5 mortality rates. Without comprehensive strategies to address morbidity and mortality associated with sickle cell disease, attainment of SDG 3.1, 3.2, and 3.4 is uncertain. Widespread data gaps and correspondingly high uncertainty in the estimates highlight the urgent need for routine and sustained surveillance efforts, further research to assess the contribution of conditions associated with sickle cell disease, and widespread deployment of evidence-based prevention and treatment for those with sickle cell disease.

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        Data show the enormous health, economic, and social cost of sickle cell disease... but recent @IHME_UW estimates are alarming, revealing that the global mortality burden of #sicklecell might be nearly 11 times higher than recorded #WorldSickleCellDay https://t.co/pVlWZ6s1G4 https://t.co/0H0gr8nV6j

    • Mashup Score: 3
      Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study - 1 year(s) ago

      Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile.

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        Online now: https://t.co/LTeaZNWgpb

    • Mashup Score: 3
      Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study - 1 year(s) ago

      Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile.

      Source: www.thelancet.com
      Categories: General Medicine News, Onc News and Journals
      Tweet Tweets with this article
      • Profile photo of 	TheLancetHaem
        TheLancetHaem

        Online now: https://t.co/LTeaZNWgpb

    Load More

    The Lancet Haematology

    @TheLancetHaem

    The Lancet Haematology is an online journal publishing original, practice-changing research, reviews, and opinion dedicated to #haematology.

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings